The results of the advisory council of experts «Place of calcimimetics in modern clinical recommendations for mbd-ckd - in the light of new studies using cincalcet»


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

March 5, 2014, an Advisory Board meeting «The Role of Calcimimetics in Current Clinical Guidelines for CKD -MBD in the Light of New Research Findings» was held in Moscow at the initiative of the Russian Dialysis Society. The Board was convened on the eve of preparation of updates to the Russian national recommendations for mineral and bone disorders in chronic kidney disease (CKD-MBD), created and published by the Russian Dialysis Society (RDS) in 2011 after publication of clinical guidelines for the diagnosis, evaluation, prevention and treatment of CKD-MBD, KDIGO 2009. Upon new clinical studies findings discussion, the experts signed the resolution.

Full Text

Restricted Access

About the authors

A. Yu Zemchenkov

Email: KLETK@INBOX.RU

References

  1. Ермоленко В.М., Волгина Г.В., Добронравов В.А. и др. Национальные рекомендации по костным и минеральным нарушениям при хронической болезни почек (май 2010 г.) // Нефрология и диализ. - 2011. - № 13(1). -С. 33-51.
  2. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) // Kidney Int Suppl. - 2009. - Vol. (113). - P. S1-130.
  3. Levey A., Eckard K.-U., Tsukamoto Y. et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO) // Kidney Int. - 2005. - Vol. 67. - P. 2089-2100.
  4. Budoff M.J., Rader D.J., Reilly M.P. et al. Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study // Am J Kidney Dis. - 2011. - Vol. 58(4). - P. 519-526.
  5. Adragão T., Pires A., Birne R. et al. A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients // Nephrol Dial Transplant. - 2009. - Vol. 24. - P. 997-1002.
  6. Raggi P., Callister T.Q., Shaw L.J. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy // Arterioscler Thromb Vasc Biol. - 2004. - Vol. 24(7). - P. 1272 -1277.
  7. Hong D., Wu S., Pu L. et al. Abdominal aortic calcification is not superior over other vascular calcification in predicting mortality in hemodialysis patients: a retrospective observational study // BMC Nephrol. - 2013. - Vol. 14(1). -P. 120.
  8. Kauppila L.I., Polak J.F., Cupples L.A. et al. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study // Atherosclerosis. - 1997. - Vol. 132(2). - P. 245-50.
  9. Земченков А.Ю., Герасимчук Р.П., Земченков Г.А. и др. Оценка сосудистой кальцификации у пациентов на гемодиализе по боковому снимку брюшной аорты. Обзор литературы и результаты пилотного исследования // Клиническая нефрология. - 2013. - № 1. - С. 29-36.
  10. Shantha G.P., Kumar A.A., Mancha A. et al. Is abdominal aortic calcification score a cost-effective screening tool to predict atherosclerotic carotid plaque and cardiac valvular calcification in patients with end-stage renal disease? // Indian J Nephrol. - 2012. - Vol. 22(6). - P. 431-437.
  11. Verbeke F., Van Biesen W., Honkanen E. et al. Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study // Clin J Am Soc Nephrol. - 2011. - Vol. 6(1). - P. 153-159.
  12. www.http: // clinicaltrials.gov/ct2/show/results/NCT00261950
  13. Evenepoel P., Claes K., Kuypers D. et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study // Nephrol Dial Transplant. - 2004. - Vol. 19(5). - P. 1281-1287.
  14. Sprague S.M., Belozeroff V., Danese M.D. et al. Abnormal bone and mineral metabolism in kidney transplant patients-a review // Am J Nephrol. - 2008. -Vol. 28(2). - P. 246-53.
  15. Casez J.P., Lippuner K., Horber F.F. et al. Changes in bone mineral density over 18 months following kidney transplantation: the respective roles of prednisone and parathyroid hormone // Nephrol Dial Transplant. - 2002. -Vol. 17(7). - P. 1318-1326.
  16. Okamoto M., Yamanaka S., Yoshimoto W. et al. Alendronate as an effective treatment for bone loss and vascular calcification in kidney transplant recipients // J Transplant. - 2014. - Vol. 2014. - P. 269613.
  17. Torregrosa J.V., Barros X. Management of hypercalcemia after renal transplantation // Nefrologia. - 2013. - Vol. 33(6). - P. 751-757.
  18. Torregrosa J.V., Morales E., Diaz J.M. et al. Cinacalcet in the management of normocalcaemic secondary hyperparathyroidism after kidney transplantation: one-year follow-up multicentre study // Nefrologia. - 2014. - Vol. 34(1). -P. 62-68.
  19. Paschoalin R.P., Torregrosa J.V., Sánchez-Escuredo A. et al. Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-term follow-up // Transplant Proc. - 2012. - Vol. 44(9). - P. 2588-2589.
  20. Evenepoel P., Sprangers B., Lerut E. et al. Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study // Clin Transplant. - 2012. - Vol. 26. -P. 393-402.
  21. Ozdemir F.N., Afsar B., Akgul A. et al. Persistent hypercalcemia is a significant risk factor for graft dysfunction in renal transplantation recipients // Transplant Proc. - 2006. - Vol. 38. - P. 480-482.
  22. Gwinner W., Suppa S., Mengel M. et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications // Am J Transplant. - 2005. - Vol. 5(8). - P. 1934-1941.
  23. Lewin E., Olgaard K. Parathyroidectomy vs calcimimetics for treatment of persistent hyperparathyroidism after kidney transplantation // Nephrol Dial Transplant. - 2006. - Vol. 21. - P. 1766-1769.
  24. Ferreira G.F., Montenegro F.L., Machado D.J. et al. Parathyroidectomy after kidney transplantation: short and long-term impact on renal function // Clinics 2011. - Vol. 66. - P. 431-435.
  25. Garcia A., Mazuecos A., Garcia T. et al. Effect of parathyroidectomy on renal graft function // Transplant Proc. - 2005. - Vol. 37. - P. 1459-1461.
  26. Cohen J.B., Gordon C.E., Balk E.M., Francis J.M. Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-analysis // Transplantation. - 2012. - Vol. 94(10). -P. 1041-1048.
  27. Evenepoel P., Cooper K., Holdaas H. et al. Poster at American Society of Nephrology, Atlanta, GA. - November 5-10, 2013.
  28. Palmer S.C., Hayen A., Macaskill P. et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis // JAMA. - 2011. - Vol. 305(11). - P. 1119-1127.
  29. Земченков А.Ю., Герасимчук Р.П., Вишневский К.А. и др. Гиперфосфатемия у пациентов с хронической болезнью почек на диализе: риски и возможности коррекции // Клиническая Нефрология. - 2013. -№ 4. - С. 13-20.
  30. Jean G., Terrat J.C., Vanel T. et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients // Nephrol Dial Transplant. - 2009. - Vol. 24(9). - P. 2792-2796.
  31. Шутов Е.В., Лашутин С.В., Люосев В.С. и др. Новые возможности в лечении вторичного гиперпаратиреоза у больных на программном гемодиализе при комбинированной терапии цинакальцетом и малыми дозами активного метаболита витамина D // Клиническая Нефрология. - 2011. - № 5. - С. 41-46.
  32. Хорошилов С.Е. Проблема кальция в фосфатсвязывающей терапии минерально-костных нарушений при хронической болезни почек у больных, получающих лечение программным гемодиализом // Клиническая Нефрология. - 2014. - № 1. - С. 36-41.
  33. Perkovic V., Neal B. Trials in kidney disease - time to EVOLVE // N Engl J Med. - 2012. - Vol. 367(26). - P. 2541-2542.
  34. Makoto Kuro-o. A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease // Kidney Int Suppl. - 2013. - Vol. 3(5). -P. 420-426.
  35. Fukagawa M., Fukuma S., Onishi Y. et al. Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study // Clin J Am Soc Nephrol. - 2012. - Vol. 7. - P. 1473-1480.
  36. Bellasi A., Reiner M., Pétavy F. et al. Presence of valvular calcification predicts the response to cinacalcet: data from the ADVANCE study // J Heart Valve Dis. - 2013. - Vol. 22(3). - P. 391-399.
  37. Hamano T. Kidney and bone update : the 5-year history and future of CKD-MBD. Pharmacoeconomics in thefield of CKD-MBD // Clin Calcium. - 2012. -Vol. 22(7). - P. 1043-1049.
  38. Sharma A., Marshall T.S., Khan S.S. et al. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA // Clin Drug Investig. - 2014. - Vol. 34(2). - P. 107-115.
  39. Belozeroff V., Lee A., Tseng S. et al. Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet // J Med Econ. - 2013. - Vol. 16(9). - P. 1154-1162.
  40. Fujii N., Hamano T., Taniguchi M. et al. Cinacalcet reduces the incidence of hip fracture in hemodialysis patients with hyperparathyroidism, hyperphosphatemia or low BMI. - Presented at ERA-EDTA 2011, Prague, Czech Republic. -Abstract SuO011.
  41. Meola M., Petrucci I., Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism // Nephrol Dial Transplant. - 2009. - Vol. 24. -P. 982-989.
  42. Komaba H., Nakanishi S., Fujimori A. et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism // Clin J Am Soc Nephrol. - 2010. - Vol. 5(12). - P. 2305-2314.
  43. Yamamoto M., Ogata H., Mizobuchi M. et al. Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism // Clin Exp Nephrol. - 2012. - Vol. 16(2). -P. 292-299.
  44. Kim J.K., Kwon Y.J., Kim S.W. et al. Rapid decrease of intact parathyroid hormone could be a predictor of better response to cinacalcet in hemodialysis patients // Yonsei Med J. - 2013. - Vol. 54(2). -P. 453-463.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies